MaxCyte, Inc. (LON:MXCT – Get Free Report)’s share price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 1.46 and traded as low as GBX 0.89. MaxCyte shares last traded at GBX 0.91, with a volume of 1,786,602 shares changing hands.
MaxCyte Stock Performance
The firm has a market cap of £924,018.43, a P/E ratio of -0.02 and a beta of 1.13. The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81. The business’s 50-day simple moving average is GBX 1.46 and its 200 day simple moving average is GBX 1.56.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Featured Articles
- Five stocks we like better than MaxCyte
- Your Bank Account Is No Longer Safe
- [No Brainer Gold Play]: “Show me a better investment.”
- This $15 Stock Could Go Down as the #1 Stock of 2026
- What a Former CIA Agent Knows About the Coming Collapse
- Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
